Skip to content
17 | 09 | 2024
—clinical

Espansione Group Announces MeiboMetrics: an Innovative, AI-powered Algorithm for Meibomian Gland Segmentation & Quantitative Measurement

 

Espansione Group is proud to announce MeiboMetrics, a groundbreaking AI-powered algorithm for the segmentation and quantitative measurement of meibomian glands.

This innovative solution has been developed in partnership with the Institute of Biomedical and Neural Engineering at Reykjavik University, leveraging a joint effort initiated in early 2023. Espansione Group and Reykjavik University have combined their expertise in eye care and imaging technology, alongside novel capabilities in machine learning and artificial intelligence, to develop a state-of-the-art tool that promises to revolutionize the screening process for meibomian gland dysfunction.

Vis-à-vis traditional Meibographies, MeiboMetrics introduces several unprecedented advancements to the field of Meibomian Glands analysis by leveraging advanced calculations.
This enables the novel algorithm to:

  • Obtain Granular and Quantitative Measurements: MeiboMetrics provides the user with detailed data on the length, width, and area of each individual meibomian gland, providing a new standard for assessing gland dysfunction
  • AI-powered Segmentation: By tapping into artificial intelligence, MeiboMetrics automatically identifies and segments meibomian glands, matching them against its large training dataset, enhancing accuracy and providing repeatability whilst reducing the need for manual intervention
  • Elimination of Manual Contouring: Automatically segments meibomian glands without requiring manual contouring, minimizing human error, maximizing repeatability of results and streamlining clinical workflows.

Dr. Paolo Gargiulo, Full Professor, Founder and Director at Reykjavick University’s Institute for Biomedical and Neural Engineering, noted that “The software is based on a novel approach that uses sophisticate bio-imaging techniques to measure and assess meibomian glands. This new solution provides a quantitative evaluation of dry eye condition advancing the state-of-the-art technology in the field.”

MeiboMetrics represents a significant innovation in the quantitative measurement of meibomian gland dysfunction, paving the way for data-driven patient management and more personalized care.

As a testament to Espansione Group's commitment to advancing ophthalmology, the algorithm will be available on the me-check® Pro and other platforms starting from 2025, promising to set a new benchmark in the field.

 

About Reykjavik University

The role of Reykjavik University (RU) is to create and disseminate knowledge in order to enhance the competitiveness and quality of life for individuals and society, guided by good ethics,
sustainability, and responsibility.

The Institute of Biomedical and Neural Engineering (Heilbrigdistaeknisetur) is an internationally recognized research center established by the University Hospital Landspitali and Reykjavik University with the aim to improve healthcare processes and translational research in biomedicine.

Visit the university's website at en.ru.is

About Espansione Group

Espansione Group is a pioneer in the medtech industry, on a mission to develop and market innovative, non-invasive solutions for prevention and management of conditions in ophthalmology and beyond.  

The company’s certified medical solutions leverage proprietary technologies such as Light Modulation™ Low-level Light Therapy (LM™ LLLT) photobiomodulation (PBM), with an ambition to redefine standards of care by expanding on their applications, with a constant commitment to science, research and development, and customer excellence.

Strategic partnerships with the industry, a strong commitment to scientific excellence and a will to shape the future have enabled Espansione Group’s advanced medical technologies to be present in over 50 countries, serving thousands healthcare providers worldwide.

For more information, see www.espansionegroup.it

Espansione Group Press Office
press@espansione.it 
© 2024 Espansione Group, All Rights Reserved
Posted on September 17th, 2024 in Newsroom

 

Get Started Now
Get in touch to find out how you can benefit from the Espansione Ecosystem of Technologies and Solutions.

In compliance with current regulations, let us know which audience you belong to:

You must fill in the form to download the file.

I want to be updated about Espansione products and services

This field is required.
This field is required.
This field is required.
A valid email address is required.
This field is required.
This field is required.
I have read the privacy policy and the terms and conditions of the site
This field is required.
I want to be updated about Espansione products and services. You can unsubscribe at any time, by using the “unsubscribe” feature at the bottom of any communication you receive.

Thank you for contacting us.